Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140152 | 0.77 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8377420 | 0.77 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28801723 | 0.73 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL620758 | 0.73 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19668537 | 0.73 | NOTUM (0.57) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12051092 | 0.73 | THRB (0.51) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28677256 | 0.73 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12689025 | 0.73 | KDM4E (0.48) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL619636 | 0.73 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17788473 | 0.73 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | RAB9A 2968/4885NPC1 2963/4885SMN1; SMN2 4383/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | RAB9A 2912/4885NPC1 2876/4885SMN1; SMN2 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.